BioMedNewsBreaks

ThursdayAug 27, 2026 3:41 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Moves Myelin-Protecting MS Therapy to Phase 2 Development

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company focused on advancing innovative therapies and technologies. The company was featured in a recent article that discussed its efforts to advance Lucid-MS, an oral investigational therapy designed to inhibit demyelination and protect myelin in people with multiple sclerosis, as MS drug development increasingly expands beyond controlling inflammation toward neuroprotection and myelin preservation. Preclinical studies demonstrated myelin preservation and functional recovery in animal models, while the company’s Phase 1 program generated safety and pharmacokinetic data supporting further development. The U.S.…

Continue Reading

ThursdayAug 27, 2026 3:12 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Expands GelrinC Clinical and Commercial Pathways

Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC cell-free cartilage repair implant along parallel U.S. clinical and European commercial tracks, with more than half of the 80-patient pivotal Phase III SAGE study enrolled and recruitment targeted for completion in the third quarter of 2026. The FDA-approved single-arm study uses a historical microfracture control dataset owned by Regentis, and the company reports that the first 40 enrolled patients closely match the historical control group in baseline characteristics. In Europe, where GelrinC already has CE Mark approval, Regentis is preparing for broader commercialization through surgeon training, an expanding network of Centers of Excellence…

Continue Reading

ThursdayAug 27, 2026 2:32 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Marks Growth as Avenvi Expands Asset Base

Earth Science Tech (OTC: ETST) was featured in a recent article that discussed its strengthened position among OTC-listed companies through consistent financial growth, timely reporting, vertical integration, prudent capital allocation, and ownership of hard real estate assets. Revenue increased to $35.7 million in FY2026 from $33.1 million in FY2025 and $11.95 million in FY2024, while gross profit rose to $25.5 million from $24.3 million and $7.8 million. The company attributes this progress to strategic investments and acquisitions made without adding debt, particularly its purchase of Avenvi, a real estate company whose 13-property portfolio includes the Texas property housing ETST’s Mister Meds…

Continue Reading

ThursdayAug 27, 2026 12:00 pm

BioMedNewsBreaks – NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) Completes Three Large-Animal Procedures Using StereoCED(TM) Platform

NeuroOne (NASDAQ: NMTC) reported the successful completion of three large-animal procedures using its next-generation StereoCED(TM) platform as part of an ongoing preclinical epilepsy research program at the University of Minnesota. In two procedures, NeuroOne drug delivery electrodes delivered a study agent directly into targeted brain tissue while also recording intracranial electrophysiological activity from the same regions, a combination the company believes has not previously been demonstrated in convection-enhanced delivery. The procedures were designed to establish technical feasibility and validate the integrated surgical and drug delivery workflow. NeuroOne said the repeatability demonstrated across the three procedures provides additional confidence as it advances toward the planned launch of StereoCED(TM) for human investigational clinical studies later this quarter. Development…

Continue Reading

WednesdayAug 26, 2026 9:00 am

BioMedNewsBreaks – Nanox Imaging Ltd. (NASDAQ: NNOX) to Report Second-Quarter 2026 Financial Results Sept. 9

Nanox (NASDAQ: NNOX), an innovative medical imaging technology company, announced it will report financial results for the quarter ended June 30, 2026, before market open on Sept. 9, 2026. CEO and Acting Chairman Erez Meltzer and CFO Guy Nathanzon will host a conference call beginning at 8:30 a.m. ET to review the results and provide a business update. A live webcast will also be available through the Investor Relations section of the Nanox website. To view the full press release, visit https://ibn.fm/y877D About Nanox Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering…

Continue Reading

MondayAug 24, 2026 12:05 pm

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) and Secarna Report Positive Early Results From Antibody Oligonucleotide Collaboration

VERAXA Biotech (NASDAQ: VRXA) and Secarna Pharmaceuticals GmbH & Co. KG announced initial positive results from their strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (“AOCs”) for autoimmune and chronic immune diseases. In early in vitro studies, an AOC candidate combining the companies’ technologies demonstrated greater potency than the equivalent unconjugated oligonucleotide, supporting the potential of the approach to selectively deliver therapeutic oligonucleotides to disease-specific cells. The companies said they are discussing next steps in the collaboration, which VERAXA noted demonstrates the potential application of its proprietary click chemistry-powered conjugation technology beyond its primary focus on solid tumors. To view the full press release, visit https://ibn.fm/IF9Cy About VERAXA Biotech AG (NASDAQ:…

Continue Reading

FridayAug 21, 2026 3:30 pm

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Strengthens Clinical Development Path for Next-Gen Cancer Therapy

VERAXA Biotech (NASDAQ: VRXA) recently received favorable Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”) regarding the development strategy for its lead BiTAC-TCE cancer therapy, providing regulatory guidance on the program’s biological rationale, pharmacokinetics and planned non-clinical safety studies ahead of potential clinical trials. The company views the feedback as an early regulatory validation that could reduce development uncertainty and clarify the path toward the clinic. VERAXA’s lead candidate previously produced encouraging preclinical results presented at the 2026 AACR Annual Meeting, where the company reported selective targeting of cancer cells carrying two biomarkers while sparing cells with only one, potentially improving the…

Continue Reading

ThursdayAug 20, 2026 10:49 am

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Enters LOI for Exclusive Option on LAG-3 Inhibitor Program

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) entered into a non-binding letter of intent (“LOI”) with Ifowonco Informatics Incorporated as an initial step toward negotiating a definitive agreement that, if completed, would grant Onco an exclusive option relating to Ifowonco’s proprietary small-molecule inhibitor program targeting lymphocyte-activation gene 3 (“LAG-3”). The proposed collaboration is intended to combine Ifowonco’s oral small-molecule immune checkpoint technology with Onco-Innovations’ expertise in DNA damage response (“DDR”) therapeutics, translational oncology and clinical development, with the companies believing the combination of DDR inhibition and LAG-3 blockade could potentially enhance anti-tumour immune responses across multiple solid tumour indications. Ifowonco’s program is…

Continue Reading

WednesdayAug 19, 2026 1:04 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Explores Myelin Protection as New Focus in MS Treatment

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is developing Lucid-MS around the idea that multiple sclerosis disability can progress independently of relapses, known as progression independent of relapse activity (“PIRA”). A recent article discusses chronic active, or “smoldering,” lesions and compartmentalized inflammation within the central nervous system as potential contributors to ongoing tissue damage that may not be adequately addressed by therapies focused primarily on peripheral immune activity. Lucid-MS takes a different approach by targeting myelin degradation, with the goal of preserving myelin and supporting functional recovery rather than broadly…

Continue Reading

WednesdayAug 19, 2026 10:55 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Acquires Zoolzy to Expand Pharmaceutical Supply Chain and Veterinary Market Reach

Earth Science Tech (OTC: ETST), a strategic holding company focused on a diversified portfolio, announced the acquisition of Zoolzy LLC, a Doral, Florida-based wholesale distributor of active pharmaceutical ingredients (“APIs”) and finished FDA-approved prescription products. Operating from a 3,684-square-foot facility, Zoolzy is expected to integrate into ETST’s supply chain and enable its compounding pharmacies to procure APIs at competitive wholesale pricing, which the company says could increase overall profit margins. The acquisition also broadens ETST’s access to novel APIs for custom compounding and provides immediate procurement access to common veterinary medications. ETST plans to leverage the new supply line to…

Continue Reading